Platelets actively sequester angiogenesis regulators.

Clinical trials with antiangiogenic agents have not been able to validate plasma or serum levels of angiogenesis regulators as reliable markers of cancer presence or therapeutic response. We recently reported that platelets contain numerous proteins that regulate angiogenesis. We now show that accumulation of angiogenesis regulators in platelets of animals bearing malignant tumors exceeds significantly their concentration in plasma or serum, as well as their levels in platelets from non-tumor-bearing animals. This process is selective, as platelets do not take up a proportional amount of other plasma proteins (eg, albumin), even though these may be present at higher concentrations. We also find that VEGF-enriched Matrigel pellets implanted subcutaneously into mice or the minute quantities of VEGF secreted by microscopic subcutaneous tumors (0.5-1 mm(3)) result in an elevation of VEGF levels in platelets, without any changes in its plasma levels. The profile of other angiogenesis regulatory proteins (eg, platelet-derived growth factor, basic fibroblast growth factor) sequestered by platelets also reflects the presence of tumors in vivo before they can be macroscopically evident. The ability of platelets to selectively take up angiogenesis regulators in cancer-bearing hosts may have implications for the diagnosis and management of many angiogenesis-related diseases and provide a guide for antiangiogenic therapies.

[1]  J. Folkman,et al.  Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. , 2008, Blood.

[2]  T. Yip,et al.  Platelet-associated PF-4 as a biomarker of early tumor growth. , 2008, Blood.

[3]  Zhiyuan Luo,et al.  Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. , 2007, Clinical chemistry.

[4]  Lynn Hlatky,et al.  Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[6]  J. Wallace,et al.  Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[8]  M. Wojtukiewicz,et al.  Platelets and angiogenesis in malignancy. , 2004, Seminars in thrombosis and hemostasis.

[9]  G. Lip,et al.  Platelet‐derived VEGF, Flt‐1, Angiopoietin‐1 and P‐selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis , 2004, Annals of medicine.

[10]  S. Rafii,et al.  Trophic Effects of Platelets on Cultured Endothelial Cells are Mediated by Platelet-associated Fibroblast Growth Factor-2 (FGF-2) and Vascular Endothelial Growth Factor (VEGF) , 2002, Thrombosis and Haemostasis.

[11]  T. Lindahl,et al.  ADP activation induces bFGF binding to platelets in vitro , 2002, Upsala journal of medical sciences.

[12]  J. Wallace,et al.  Thrombin‐induced platelet endostatin release is blocked by a proteinase activated receptor‐4 (PAR4) antagonist , 2001, British journal of pharmacology.

[13]  J. Folkman,et al.  Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. , 2001, Journal of the National Cancer Institute.

[14]  J. Palmblad,et al.  Angiogenesis Research: Guidelines for Translation to Clinical Application , 2001, Thrombosis and Haemostasis.

[15]  Verheul,et al.  Tumor Growth: A Putative Role for Platelets? , 1998, The oncologist.

[16]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[17]  S. Rafii,et al.  Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Shuman,et al.  Endocytosis of fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha IIb beta 3 (glycoprotein IIb-IIIa) , 1993, Blood.

[19]  B. Walker,et al.  An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Paul J. Harrison,et al.  Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. , 1989, The Journal of clinical investigation.

[21]  J. George,et al.  Incorporation of a circulating protein into megakaryocyte and platelet granules. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[23]  S. Karpatkin,et al.  CHAPTER 42 – Tumor Growth and Metastasis , 2007 .

[24]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[25]  R. Bast,et al.  for the Detection of Early Stage Ovarian Cancer Three Biomarkers Identified from Serum Proteomic Analysis , 2004 .

[26]  H. K. Kim,et al.  Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. , 2003, European journal of cancer.